2020

Test Material from Large Scale Production Delivered

The first samples of test material from the upscaling to large-scale production of Nanologica’s silica have been delivered. Upscaling to large-scale production of Nanologica’s silica started in July 2019. The silica is produced according to Nanologica’s proprietary methods at the contract manufacturer Sterling Pharma Solutions in the UK. The first samples of test material have now been delivered. ” It is very pleasing to having received the first test material from the large-scale production. This

Read more »

DDL 2020 – Drug Delivery to the Lungs Conference

Nanologica is attending the Drug Delivery to the Lungs conference (DDL) during Dec 9-11. The DDL is the premier conference and industry exhibition which is dedicated to pulmonary and nasal drug delivery. The focus is on providing a forum to present t recent developments in the field of inhalation therapy. Representing Nanologica is Prof. Adam Feiler, CTO.

Read more »

Inlösen av optionsprogram i Nanologica AB

Delar av Nanologicas optionsprogram 2018/21 har lösts in av optionsinnehavarna, vilket medför en ökning av antalet aktier i bolaget med 77 773 till 27 776 850 aktier. Aktiekapitalet ökar som en följd av detta med 31 886,93 SEK till 11 389 278,16 SEK.   Vid Nanologicas årsstämma den 31 maj 2018 beslutades om att inrätta ett incitamentsprogram om maximalt 484 883 teckningsoptioner för bolagets anställda. Varje teckningsoption ger rätten att teckna en aktie i bolaget till en teckningskurs motsvarande

Read more »